DW1350, a Newly Synthetic Anti-osteoporotic Agent: 1. DW-1350 Inhibited Bone Resorption and Promoted Bone Formation

  • Lee, Jin-Soo (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Ltd) ;
  • Whang, Yun-Ha (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Ltd, Biochemistry Department, Seoul National University) ;
  • Ahn, Seok-Hoon (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Lt) ;
  • PanSoo (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Lt) ;
  • Jin, Sang-Mi (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Lt) ;
  • Yi, Sun-Shin (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Lt) ;
  • Jung, Young-Ho (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Lt) ;
  • Suh, Hong-Suk (Department of Chemistry, Pusan National University) ;
  • Ryu, Jei-Man (Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Ltd)
  • Published : 2003.04.01

Abstract

Recently, we developed a new anti-osteoporotic agent, DW-1350, which not only inhibited osteoclast formation but also induced osteoblast differentiation through the in vitro randomized screening studies. We identified inhibitory activities of DW-1350 for each step of osteoclast differentiation, fusion and pit formation process in co-culture system with mouse bone marrow and primary osteoblasts. (omitted)

Keywords